Matthew Foehr Sells 20,754 Shares of OmniAb (NASDAQ:OABI) Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew Foehr sold 20,754 shares of OmniAb stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $1.70, for a total value of $35,281.80. Following the transaction, the chief executive officer owned 4,375,787 shares of the company’s stock, valued at $7,438,837.90. The trade was a 0.47% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

OmniAb Price Performance

OmniAb stock traded up $0.01 during mid-day trading on Tuesday, reaching $1.71. The stock had a trading volume of 329,952 shares, compared to its average volume of 376,779. The company has a 50-day moving average price of $1.90 and a two-hundred day moving average price of $1.76. The company has a market capitalization of $246.16 million, a price-to-earnings ratio of -2.95 and a beta of 0.13. OmniAb, Inc. has a one year low of $1.22 and a one year high of $4.02.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OmniAb in a report on Monday, December 22nd. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $6.67.

Hedge Funds Weigh In On OmniAb

Hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. increased its position in shares of OmniAb by 214.4% during the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company’s stock valued at $25,000 after purchasing an additional 9,716 shares during the last quarter. AQR Capital Management LLC purchased a new position in shares of OmniAb during the 1st quarter worth about $25,000. BNP Paribas Financial Markets grew its holdings in OmniAb by 92.5% during the 3rd quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company’s stock valued at $35,000 after purchasing an additional 10,438 shares during the last quarter. Cerity Partners LLC raised its position in OmniAb by 111.5% in the 2nd quarter. Cerity Partners LLC now owns 22,612 shares of the company’s stock worth $39,000 after purchasing an additional 11,919 shares during the period. Finally, SG Americas Securities LLC boosted its position in shares of OmniAb by 96.6% during the fourth quarter. SG Americas Securities LLC now owns 23,141 shares of the company’s stock valued at $43,000 after buying an additional 11,369 shares during the period. Hedge funds and other institutional investors own 72.08% of the company’s stock.

OmniAb Company Profile

OmniAb, Inc (NASDAQ: OABI) operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.